Octagos vs OpenEvidence

Octagos processes remote monitoring transmissions from cardiac implants for clinics that run a device program. A 2025 JACC Advances study covered 690,673 transmissions from 74,217 devices at 78 US clinics. The vendor's page reads it as Atlas AI at 99.1% sensitivity against 70.8% for technicians. Octagos is linked to that study, so it is not independent confirmation. The vendor's Two Brain Approach has Atlas AI do the first analysis, a specialist finalize it, and a physician e-sign every report.

OpenEvidence draws on content from NEJM and JAMA partners, and access is free for physicians with a verified NPI. Sacra and other secondary write-ups say its revenue is mostly pharmaceutical advertising. A resident or hospitalist who wants a cited answer mid-shift suits OpenEvidence. A cardiology clinic running a device program suits Octagos, whose job is deciding which implant transmissions reach a clinician.